Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 12, 2019. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. It does not contain financial results, operational updates, or strategic commentary for the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not report on the company's financial performance.
Material Changes and Transaction Details
The filing details nine separate transactions executed on March 11, 2019, on the London Stock Exchange (XLON). All transactions involved the acquisition of Ordinary Shares (ISIN: GB0009252882) under the Company's Share Reward Plan. The transactions were conducted at a uniform price of £15.2759 per share.
- Ms E Walmsley (CEO): Acquired 16 shares (8 partnership, 8 matching).
- Mr R G Connor (President, Global Vaccines): Acquired 16 shares (8 partnership, 8 matching).
- Mr S Dingemans (CFO): Acquired 16 shares (8 partnership, 8 matching).
- Mr N Hirons (SVP, Global Ethics & Compliance): Acquired 16 shares (8 partnership, 8 matching).
- Mr D S Redfern (Chief Strategy Officer): Acquired 16 shares (8 partnership, 8 matching).
- Mr R Simard (President, Pharma Supply Chain): Acquired 16 shares (8 partnership, 8 matching).
- Ms C Thomas (SVP, Human Resources): Acquired 16 shares (8 partnership, 8 matching).
- Mr P C Thomson (President, Global Affairs): Acquired 18 shares (9 partnership, 9 matching).
- Mrs V A Whyte (Company Secretary): Acquired 16 shares (8 partnership, 8 matching).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory reporting of the aforementioned share acquisitions.
Key Facts for Investor Verification
- Verify the total volume of shares acquired by PDMRs (146 shares total) against the company's broader share buyback or compensation programs.
- Confirm the transaction price of £15.2759 aligns with the market price of GSK ordinary shares on March 11, 2019.
- Note that these transactions are part of the Share Reward Plan, indicating standard executive compensation rather than open-market speculation.
- Recognize that this filing contains no financial performance data; investors must refer to Form 20-F or quarterly reports for revenue and earnings metrics.